Bosc, M., Dubini, A., & Polin, V. (1997). Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. European Neuropsychopbarmacology, 7 (Suppl. 1), S57-S70.
2.
Burrows, G. D., Maguire, K. P., & Norman, T. R. (1998). Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: A review. journal of Clinical Psychiatry, 59 (Suppl. 14), S4-S7.
3.
Charney, D. S. (1998). Monoamine dysfunction and the pathophysiology and treatment of depression. Journal of Clinical Psychiatry, 59(Suppl. 14), S11-S14.
4.
DeVane, C. L. (1998). Differential pharmacology of newer antidepressants. Journal of Clinical Psychiatry, 59 (Suppl. 20), S85-S93.
5.
Dostert, P., Benedetti, M. S., & Poggesi, I. (1997, April). Review of pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. European Neuropsychopharmacology. (Suppl 1), S23-S35.
6.
Dubini, A., Bosc, M., & Polin, V. (1997). Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning. Journal of PPsycbopharmacologyo11 (Suppl. 4), S17-S23.
7.
Ereshefsky, L. (1999, October). Drug interactions. Presented at Advances in Psychopharmacology 1999, Salt Lake City, UT.
8.
Hamilton, M. (1960). A rating scale for depression. Journal of Neurological and Neurosurgical Psychiatry, 23, 56-62.
9.
Massana, J. (1998). Reboxetine versus fluoxetine: An overview of efficacy and tolerability. Journal of Clinical Psychiatry, 59 (Suppl. 14), S8-S10.
10.
Montgomery, S. A. (1997). Reboxetine: Additional benefits to the depressed patient. Journal of Psychopharmacology, 11 (Suppl. 4), S9-S15.
11.
Montgomery, S. A. (1998). Chairman's Overview: The place of reboxetine in antidepressant therapy. Journal of Clinical Psychiatry, 59 (Suppl. 14), S26-S29.
12.
Montgomery, S. A., & Schatzberg, A. F. (1998). Reboxetine: A new selective antidepressant for the treatment of depression. Jou rnal of Clinical Psychiatri, 59 (Suppl. 14), S1-S1.
13.
Mucci, M. (1997). Reboxetine: A review of antidepressant tolerability. Journal of Psychopharmacologic11 (Suppl. 4), S33-S37.
14.
Riva, M., Brunello, N., Rovescalli, A.C., et al. (1989). Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: Behavioral and biochemical studies. Journal of Drug Developmnent, 1, 243-253.
15.
Schatzberg, A. F. (1998). Noradrenergic versus serotonergic antide pressants: Predictors of treatment response. Journal of Clinical Psychiatry, 59 (Suppl. 14), S15-S18.
16.
Stahl, S. M. (1996). Essential psychopharnmacology. New York: Cambridge University Press.
17.
Versiani, M., Mehilane, L., Gaszner, P., & Arnaud-Castiglioni, R. (1999). Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. Journal of Clinical Psychiatry, 60, 400-406.
